Introduction
exclude any antiviral or cytotoxic effect of DMSO. They were stored at -20°C until use. Human recombinant TNF-α was purchased from Boehringer (Mannheim, Germany).
Cells
The promonocytic cell line U1 was used in the antiviral assays (Folks et al., 1987) . U1 cells are chronically infected with HIV-1. They produce little or no viral particles and antigens under basal conditions, but do produce significant levels of viral proteins after stimulation with various sub-stances, such as TNF-α and PMA (Butera et al., 1994) . U1 cells were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin G, 100 µg/ml streptomycin (culture medium).
Antiviral assay
The anti-HIV-1 activity of cepharanoline derivatives was based on the inhibition of viral antigen production in stimulated U1 cells. The cells (1×10 5 cells/ml) were incubated at 37°C in the absence or presence of the compounds for 2 h, stimulated with 1 ng/ml TNF-α, and further incubated for 3 days. The culture supernatants were then collected and examined for their p24 antigen levels with a sandwich enzyme-linked immunosorbent assay kit (ZeptoMetrix, Bufallo, NY, USA). The cytotoxicity of cepharanoline derivatives was evaluated in parallel with their antiviral activity. Cytotoxicity was based on the reduction of viable cell number determined by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] method (Pauwels et al., 1988) . All experiments were carried out three times.
Results
In the first set of experiments, 28 cepharanoline derivatives (Figure 1 ), including cepharanthine, were examined for their inhibitory effects on HIV-1 replication in TNF-αstimulated U1 cells. For accurate activity comparison, all compounds were tested at the same time, and the assay was repeated three times. The 28 compounds were divided into three groups, that is, 12-O-alkyl, 12-O-acyl and 12-O-carbamoyl derivatives. When the compounds were tested at a concentration of 0.1 µg/ml, cepharanthine proved be the most active. It reduced the p24 antigen levels in the culture supernatants to 26.3 ±3.2% of the control (Figure 3 ). Cepharanoline was a much less potent inhibitor than cepharanthine. It displayed marginal inhibition of p24 antigen production at a concentration of 0.1 µg/ml. Compound 3 (12-O-ethyl cepharanoline) was also active, reducing the p24 antigen levels to 36.0 ±3.6% of the control. Interestingly, the activity decreased with increasing the length of the alkyl chain. All of the 12-O-acyl derivatives were inactive, however two 12-O-carbamoyl derivatives (compounds 20 and 21) showed modest activity ( Figure 3 ). None of the compounds affected the viability and proliferation of U1 cells at this concentration (data not shown).
In the next set of experiments, an additional 23 derivatives were examined for their anti-HIV-1 activity. Cepharanthine was always included in the assays as the reference compound. As shown in Figure 4 , three derivatives (compounds 35, 40 and 41) proved to be potent inhibitors of HIV-1 replication. Compounds 35, 40 and 41 could reduce the p24 antigen levels to 20.5 ±14.5, 22.7 ±13.7 and 21.9 ±12.6% of the control, respectively, at a concentration of 0.1 µg/ml. These values were almost identical or even slightly better than that achieved by cepharanthine (27.4 ±10.4%). The 50% effective concentrations (EC 50 ) of compounds 35, 40, 41 and cepharanthine were 0.017 ±0.005, 0.022 ±0.004, 0.023 ±0.004 and 0.024 ±0.012 µg/ml, respectively (data not shown). Again, all of the compounds did not show any cytotoxicity to U1 cells at 0.1 µg/ml (data not shown).
Since the active compounds (35, 40 and 41) were 12-Oethyl derivatives, we further synthesized this class of compounds and examined for their activity. Among the 46 compounds ( Figure 2 ), more than half of them displayed selective inhibition of HIV-1 replication at a concentration of 0.1 µg/ml ( Figure 5 ). Five compounds (57, 68, 78, 93 and 97) were found to be more active than cepharanthine. Although cepharanthine reduced the p24 antigen levels to 20.9 ±5.8% of the control in this set of experiments, compounds 57, 68, 78, 93 and 97 achieved the antigen levels that were 11.0 ±2.5, 13.6 ±5.5, 13.3 ±5.8, 9.2 ±1.4 and 14.0 ±3.0% of the control, respectively. Table 1 shows the anti-HIV-1 activity and cytotoxicity of the five compounds. The most active was compound 93 (12-O-ethyl- All data represent means ±SD for three separate experiments. EC 50 , 50% effective concentration required to inhibit HIV-1 p24 antigen production in U1 cells; CC 50 , 50% cytotoxic concentration required to inhibit the viability and proliferation of U1 cells; SI, selectivity index based on the ratio of EC 50 to CC 50 .
Figure 3. Inhibitory effects of cepharanoline derivatives on HIV-1 replication in U1 cells (1)
Cells were incubated at 37°C in the absence or presence (0.1 µg/ml) of the compounds, stimulated with TNF-α (1 ng/ml), and further incubated for 3 days. The culture supernatants were examined for their p24 antigen levels. The p24 antigen levels were expressed as the percent of the control (the level in the absence of compounds). All data represent means ±SD for three separate experiments. piperazinyl cepharanoline). The EC 50 of compound 93 and cepharanthine were 0.0041 ±0.0020 and 0.028 ±0.016 µg/ml (0.0060 ±0.0029 and 0.046 ±0.026 µM), respectively. In the same assay system, the EC 50 of cepharanthine and the protease inhibitor nelfinavir were previously reported to be 0.047 ±0.005 and 0.13 ±0.01 µM, respectively (Okamoto et al., 1999) . By contrast, the 50% cytotoxic concentrations (CC 50 ) of compound 93 and cepharanthine were 1.2 ±0.6 and 1.3 ±0.3 µg/ml (1.7 ±0.9 and 2.1 ±0.5 µM), respectively, indicating that compound 93 was about sevenfold more potent and selective as an inhibitor of HIV-1 replication in U1 cells than cepharanthine.
Discussion
Recent development of the highly active antiretroviral therapy (HAART) with reverse transcriptase inhibitors and protease inhibitors in HIV-1-infected patients has achieved more than a 2 log 10 reduction of viral RNA levels in plasma for a considerable period of time (see Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents by Department of Health and Human Services, 2000, www.iapac.org/guidelines/index.html). Since these inhibitors have potent antiviral activity but narrow antiviral spectrum, the emergence of drug-resistant viruses caused by amino acid mutations of the enzymes is still a serious concern during long-term treatment (Schinazi et al., 2000) . By contrast, the inhibitors that interact with host cellular factors may not easily generate drug-resistance but may cause considerable side-effects because of their low specificity to the virus. Thus, the use of such compounds for the treatment of HIV-1 infection would be limited, unless they could have a certain degree of selectivity for HIV-1 replication or a favourable effect on host-cellular machinery (Baba, 2001; Butera, 2000) .
It is well recognized that HIV-1 gene expression is strongly enhanced by stimulation with inflammatory cytokines, such as TNF-α and interleukin-1β, primarily through activation and binding of cellular transcription factors to the enhancer elements in the HIV-1 long terminal repeat (Osborn et al., 1989) . Among the cellular transcription factors, NFκB is the most potent activator of HIV-1 gene expression (Griffin et al., 1989; Nabel & Baltimore, 1987) . In fact, the expression of HIV-1 mRNA is strongly enhanced with low concentrations of TNF-α through the activation of NFκB in chronically infected cells (Butera et al., 1994; Baba et al., 1997) . Cepharanthine is a natural substance (plant alkaloid) that has recently been shown to inhibit TNF-α-induced HIV-1 production in U1 cells through the suppression of NFκB activation (Okamoto et al., 1998) .
After the discovery of cepharanthine as an anti-HIV-1 agent, we have attempted to obtain more active and selective analogues by modifying the molecule at position 12, since cepharanthine (12-O-methyl cepharanoline) is much more active than cepharanoline itself. The assay results on the first series (compounds 1-28) clearly indicated that 12-O-alkyl group was important for the anti-HIV-1 activity of cepharanoline (Figures 1 and 3) . The results on the second series (compounds 29-51) further suggested that 12-Oethyl derivatives looked promising (Figures 1 and 4) . Therefore, a number of 12-O-ethyl derivatives have been synthesized and examined for their anti-HIV-1 activity. Consequently, five compounds were found to be more potent inhibitors of HIV-1 replication then cepharanthine (Table 1 ). In particular, compound 93 (12-O-ethylpiperazinyl cepharanoline) was highly potent and selective.
It should be noted that cepharanthine is not inhibitory to HIV-1 replication in acutely infected cells (data not shown). The reason for the inactivity of cepharanthine in acute HIV-1 infection is unclear. A plausible explanation is that the viral protein Tat may play a much more crucial role in HIV-1 gene expression than NFκB in acutely infected cells. Therefore, once a small amount of Tat is produced in the infected cells, Tat may predominantly drive HIV-1 gene expression. Furthermore, the U1 cell line, which contains two integrated HIV-1 proviruses, was defective at the level of Tat function due to the mutation of each tat gene (Emiliani et al., 1998) . This observation may explain why HIV-1 replication in U1 cells is affected by the state of NFκB activation and is sensitive to the NFκB inhibitor cepharanthine. However, it cannot be excluded that the activity of cepharanthine is not potent enough to inhibit HIV-1 replication in acutely infected cells. In fact, the most active derivative (compound 93) showed some inhibition of HIV-1 replication in acutely infected CEM cells (40% inhibition at 5 µM). Further studies are in progress to elucidate this point.
A possible application of cepharanthine is the prophylaxis and therapy of HIV-1-associated disorders of the central nervous system (CNS). Brain macrophages and microglia are major target cells of HIV-1 in the brain, and are known to produce viral proteins, inflammatory cytokines and oxidants, which could contribute to the CNS damage (Merrill & Chen, 1991; Epstein & Gendelman, 1993; Yeung et al., 1995) . We have recently found that cepharanthine suppresses inflammatory cytokine production in human primary monocyte/macrophages (Okamoto et al., 2001) . Furthermore, the compound also inhibited TNF-α-and HIV-1 gp120-induced neural cell death in cell cultures. Thus, cepharanthine and the active derivatives identified in this study should be investigated further for their therapeutic potential in HIV-1 infection and its complications.
